Fig. 2: Brolucizumab treatment framework for patients with nAMD. | Eye

Fig. 2: Brolucizumab treatment framework for patients with nAMD.

From: The changing landscape for the management of patients with neovascular AMD: brolucizumab in clinical practice

Fig. 2

*For further information see expert opinion for guidance. **Recommended dose is 6 mg brolucizumab (0.05 ml solution). BCVA best-corrected visual acuity; DA, disease activity, ETDRS early treatment diabetic retinopathy study, IOI intraocular inflammation, IOP intraocular pressure, nAMD neovascular age-related macular degeneration, OCT optical coherence tomography, RO retinal vascular occlusion, VA visual acuity. 1. Beovu SmPC. Available at: https://www.ema.europa.eu/en/documents/product-information/beovu-epar-product-information_en.pdf. Accessed February 2021; 2. NICE. TA672. Available at: https://www.nice.org.uk/guidance/TA672. Accessed February 2021; 3. RCOphth. AMD Services Commissioning Guidance Available at: https://www.rcophth.ac.uk/wp-content/uploads/2021/02/AMD-Commissioning-Guidance-Consultation.pdf. Accessed February 2021; 4. Zarbin M, et al. American Academy of Ophthalmology Annual Meeting, 13–15 November 2020; 5. German Society of Ophthalmology (Deutsche Ophthalmologische Gesellschaft, DOG); German Retina Society (Retinologische Gesellschaft e. V, RG); Professional Association of German Ophthalmologists (Berufsverband der Augenärzte Deutschlands e. V, BVA) Ophthalmologe 2021;118(Suppl 1):31–39.

Back to article page